. Author manuscript; available in PMC: 2011 May 1.

Published in final edited form as: Am J Prev Med. 2010 May;38(5):482–490. doi: 10.1016/j.amepre.2010.01.024

Table 3.

Seven and 30-day point prevalence abstinence at 3 and 6 months by treatment group

Follow-up point	7-Day Point Prevalence Abstinence, %	OR (95% CI) for comparison to web	OR (95% CI) for comparison to PTC
3 months
Web	38.9
PTC	48.5	1.48 (1.12, 1.96)^*
PTC–web	43.4	1.20 (0.91, 1.59)	0.81 (0.62, 1.07)
6 months
Web	30.7
PTC	34.3	1.18 (0.86, 1.56)
PTC–web	33.8	1.16 (0.88, 1.59)	0.98 (0.73, 1.31)
	*30-Day Point Prevalence Abstinence, %*	*OR (95% CI) for comparison to web*	*OR (95% CI) for comparison to PTC*

3 months
Web	32.7
PTC	42.0	1.50 (1.12, 1.99)^*
PTC–web	39.1	1.32 (0.99, 1.77)	0.88 (0.67, 1.17)
6 months
Web	27.4
PTC	30.6	1.17 (0.86, 1.58)
PTC–web	30.3	1.15 (0.85, 1.56)	0.99 (0.73, 1.33)

P < 0.05.